TUMOR BIOLOGY AND MICROENVIRONMENT (TBM) ? ABSTRACT The Tumor Biology and Microenvironment (TBM) Program is a translational science program that aims to discover the cellular and molecular determinants that drive the initiation and progression of cancers through interactions with their microenvironments and develop and test innovative diagnostic and treatment strategies. This highly integrated Program includes 37 members from 13 departments and 4 schools at Wayne State University. TBM Program members, who conduct basic, preclinical, and clinical research, receive $4,468,183 in peer reviewed, cancer-related grant support, of which $1,943,419 is from the NCI. The TBM Program is organized along three major themes. The goal of the first theme is to explore biological processes that mediate the phenotypical plasticity, proliferation, and survival of tumor cells. Translational research is conducted to evaluate the potential clinical application of these molecular determinants as tumor markers and/or therapeutic targets. The second theme investigates mechanisms that enable tumor cells to overcome external barriers during invasion and metastasis. Our investigators assess the importance of factors that control extracellular proteolysis and signaling mechanisms that are being used by tumor cells to adapt to and subvert the microenvironment at primary and metastatic sites. The objective of the third theme is to develop new strategies to engage the immune system as powerful defenses against cancer. Research activities include the development of immune modulators and novel vehicles to optimally deliver immunotherapeutics, as well as the use of state-of-the art imaging modalities for monitoring the success to tumor immunotherapy. The TBM Program is led by Dr. Kay-Uwe Wagner as Program Leader and Dr. Asfar Azmi as Program Co-Leader. The Leader and Co-Leader are new since the last competitive renewal. All members of the TBM Program actively collaborate with members of the MI, MT, and PSDR Programs at KCI. Of the 484 manuscripts published between December 2015 and November 2019, 41% and 44% were intra- and inter-programmatic, respectively, and 61% were multi-institutional collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088976
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319
Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238
Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298
Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993
Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203
Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47

Showing the most recent 10 out of 826 publications